Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
Zhong YuanBennett LevitanHsiaowei DengMichael SzarekRupert M BauersachsScott D BerkowitzLloyd P HaskellElliot S BarnathanMarc P BonacaPublished in: Journal of the American Heart Association (2024)
These analyses show a favorable benefit-risk profile of rivaroxaban therapy in the VOYAGER PAD trial, with findings generally consistent between the unweighted and weighted approaches.
Keyphrases
- end stage renal disease
- venous thromboembolism
- atrial fibrillation
- study protocol
- clinical trial
- pulmonary embolism
- phase iii
- newly diagnosed
- ejection fraction
- phase ii
- chronic kidney disease
- magnetic resonance
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- high resolution
- stem cells
- percutaneous coronary intervention
- computed tomography
- mesenchymal stem cells
- bone marrow
- mass spectrometry
- open label
- placebo controlled